|
Outcomes of Pharmaceutical Care Development in Pediatric Patients with Thalassemia Using Deferiprone in Phrae Hospital |
|---|---|
| รหัสดีโอไอ | |
| Creator | Sumalee Sanguansak |
| Title | Outcomes of Pharmaceutical Care Development in Pediatric Patients with Thalassemia Using Deferiprone in Phrae Hospital |
| Contributor | Wannakamol Sonsingh, Kanokporn Niwatananun |
| Publisher | Faculty of Pharmaceutical Sciences KKU MSU UBU |
| Publication Year | 2559 |
| Journal Title | Isan Journal of Pharmaceutical Sciences |
| Journal Vol. | 12 |
| Journal No. | 1 |
| Page no. | 13-24 |
| Keyword | deferiprone, thalassemia, pharmaceutical care, drug therapy problems |
| URL Website | https://tci-thaijo.org/index.php/IJPS |
| Website title | Isan Journal ofPharmaceutical Sciences,IJPS |
| ISSN | 19050852 |
| Abstract | Introduction: Thalassemia patients with iron overload and had to take iron chelator-deferiprone likely to have drug therapy problems (DTPs) that affected the treatment outcome assessed by an unmet goal of reduction in serum ferritin levels and incidence of adverse events. Therefore, pharmaceutical care services were developed to solve the problems. . This study aimed to evaluate the outcome of pharmaceutical care development in pediatric thalassemia patients taking derferiprone by assessing reduction of serum ferritin levels and occurrence of DTPs. Materials and Method: A quasi-experimental research, with one group pretest-posttest design was carried out in 39 pediatric thalassemia patients taking deferiprone and visiting at the Department of Pediatrics, Phrae Hospital during October 1, 2010 to May 31, 2015. The study period was divided into three periods, including pre-pharmaceutical care, the first phase of pharmaceutical care and the second phase of pharmaceutical care. Results: Mean serum ferritin levels in month 0, 6 and 12 during the first phase of pharmaceutical care decreased significantly (2316.4, 1695.1 and 1269.7 nanogram/milliliter respectively; p <0.001), whereas serum ferritin levels in months 0, 6 and 12 of pre- pharmaceutical care period and the second phase of pharmaceutical care were not different (p = 0.347). Based on 22 patients who have serum ferritin levels in all three phases. In addition, number of non-compliance significantly declined in the second phase of pharmaceutical care compared to those in the first phase of pharmaceutical care (p=0.019) (n=39). Conclusion: Outcome of pharmaceutical care development can reduce serum ferritin levels, and resolves non-compliance, in pediatric thalassemia patients. |
